Rezultati - David Lucas
- Showing 1 - 20 results of 45
- Go to Next Page
-
1
-
2
Seafarers’ Occupational Noise Exposure and Cardiovascular Risk. Comments to Bolm-Audorff, U.; et al. Occupational Noise and Hypertension Risk: A Systematic Review and Meta-Analysis... od David, Lucas, Brice, Loddé, Richard, Pougnet, Jean Dominique, Dewitte, Dominique, Jégaden
Izdano 2021Text -
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction od John C. Byrd, Shinichi Kitada, Ian W. Flinn, Jennifer L. Aron, Michael Pearson, David Lucas, John C. Reed
Izdano 2002Artigo -
11
-
12
-
13
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia od Amy J. Johnson, David Lucas, Natarajan Muthusamy, Lisa L. Smith, Ryan B. Edwards, Michael De Lay, Carlo M. Croce, Michael R. Grever, John C. Byrd
Izdano 2006Artigo -
14
Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism... od Kristie A. Blum, Sin‐Ho Jung, Jeffrey L. Johnson, Thomas S. Lin, Eric D. Hsi, David Lucas, John C. Byrd, Bruce D. Cheson, Nancy L. Bartlett
Izdano 2010Artigo -
15
Daunorubicin‐Loaded DNA Origami Nanostructures Circumvent Drug‐Resistance Mechanisms in a Leukemia Model od Patrick D. Halley, Christopher R. Lucas, Emily M. McWilliams, Matthew J. Webber, Randy A. Patton, Cömert Kural, David Lucas, John C. Byrd, Carlos E. Castro
Izdano 2015Artigo -
16
Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Ad... od John C. Byrd, John G. Gribben, Bercedis L. Peterson, Michael R. Grever, Gerard Lozanski, David Lucas, Ben Lampson, Richard A. Larson, Michael A. Caligiuri, Nyla A. Heerema
Izdano 2005Artigo -
17
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL od Shih-Shih Chen, Rainer Claus, David Lucas, Lianbo Yu, Qian Jiang, Amy S. Ruppert, Derek A. West, Katie Williams, Amy J. Johnson, Fred Sablitzky, Christoph Plass, John C. Byrd
Izdano 2010Artigo -
18
Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease od Javier Bolaños‐Meade, David A. Jacobsohn, Jeffrey Margolis, Adam Ogden, M. Guillaume Wientjes, John C. Byrd, David Lucas, Viki Anders, Michele Phelps, Michael R. Grever, Georgia B. Vogelsang
Izdano 2005Artigo -
19
-
20
Persistence of<i>DNMT3A</i>R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia od Bhavana Bhatnagar, Ann‐Kathrin Eisfeld, Deedra Nicolet, Krzysztof Mrózek, James S. Blachly, Shelley Orwick, David Lucas, Jessica Kohlschmidt, William Blum, Jonathan E. Kolitz, Richard M. Stone, Clara D. Bloomfield, John C. Byrd
Izdano 2016Artigo
Iskalna orodja:
Sorodne teme
Biology
Leukemia
Medicine
Chronic lymphocytic leukemia
Internal medicine
Cancer research
Immunology
Biochemistry
Gene
Genetics
Chemotherapy
Oncology
Pharmacology
Gastroenterology
In vivo
Lymphoma
Biotechnology
Chemistry
Cyclophosphamide
DNA methylation
Gene expression
In vitro
Apoptosis
Fludarabine
Computational biology
Methylation
Rituximab
Toxicity
Astrobiology
Cancer